Arglabin targets a non-canonical NLRP3/CCR2 axis to suppress MDSC infiltration and potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma.
BACKGROUND Hepatocellular carcinoma (HCC) develops in an immunosuppressive tumor microenvironment characterized by NLRP3 overexpression, in which myeloid-derived suppressor cells (MDSCs) are abundantly enriched and play a critical role in compromising T cell-mediated antitumor immunity. Arglabin (Arg), a natural sesqui...